17/#454 First-line maintenance among advanced ovarian cancer patients in the us oncology network: a real-world retrospective cohort study

Abstract

and duration of response (DOR) with addition of RELA. We present a post-hoc subgroup analysis in patients with/without prior bevacizumab. Methods 178 women with recurrent, platinum-resistant/refractory ovarian, primary peritoneal, or fallopian tube cancer or ovarian carcinosarcoma with £4 prior lines of chemotherapy (105 with; 73 without prior bevacizumab) were enrolled in a phase 2, open-label, randomized study (NCT03776812). Data for patients receiving either NP (80 mg/m 2 ) + intermittent RELA (150 mg QD the day before, of, and after NP) (n=60) or NP alone (100 mg/m 2 ) (n=60) are reported. Results Baseline characteristics in the 2 groups were generally balanced. While patients without prior bevacizumab were balanced between North America and Europe, 70% of patients who received prior bevacizumab were in Europe. PFS, OS, ORR, and DOR are shown in table 1. Conclusions In this subgroup analysis, patients who had received prior bevacizumab had better PFS, OS, and DOR with intermittent RELA+NP vs NP alone, while ORR was similar across all groups. Numerical improvement in PFS was seen in patients without prior bevacizumab. Prior bevacizumab will be a stratification factor in the phase 3 trial of RELA +NP (ROSELLA, NCT05257408) that is planned to start in mid-2022.